COMPARISON OF ANALYSIS APPROACHES FOR PHASE III CLINICAL TRIALS IN AMYOTROPHIC LATERAL SCLEROSIS

被引:20
作者
Healy, Brian C. [1 ,2 ]
Schoenfeld, David [1 ,3 ]
机构
[1] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA
[2] Brigham & Womens Hosp, Partners MS Ctr, Brookline, MA USA
[3] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
关键词
amyotrophic lateral sclerosis; clinical trial; longitudinal analysis; sample size calculations; survival analysis; PLACEBO-CONTROLLED TRIAL; FUNCTIONAL RATING-SCALE; LONGITUDINAL DATA; ALS; MODELS; MULTICENTER;
D O I
10.1002/mus.23392
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: In this study we explore several methods for incorporating survival information in the analysis of Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) scores. Methods: ALSFRS scores and patient survival times were simulated based on estimates from a recent clinical trial. Six analysis approaches were applied to the data. Each approach was based on ALSFRS scores, the survival time, or a combination of the 2. The power of each approach to detect potential treatment effects was estimated. Results: When the treatment acted solely on the change in ALSFRS, the shared parameter model provided the most power, although all of the models based on random effects were similar. As the effect on survival increased, rank-based analysis showed potential gains in power. Survival analysis was superior under a small effect on ALSFRS and a larger effect on mortality. Conclusions: The shared parameter model and rank-based approach can offer improvements in power over traditional approaches. Muscle Nerve 46: 506-511, 2012
引用
收藏
页码:506 / 511
页数:6
相关论文
共 18 条
[1]   USE OF COMPOSITE SCORES (MEGASCORES) TO MEASURE DEFICIT IN AMYOTROPHIC LATERAL SCLEROSIS [J].
ANDRES, PL ;
FINISON, LJ ;
CONLON, T ;
THIBODEAU, LM ;
MUNSAT, TL .
NEUROLOGY, 1988, 38 (03) :405-408
[2]  
[Anonymous], 1996, ARCH NEUROL, V53, P141
[3]   Performance of the amyotrophic lateral sclerosis functional rating scale (ALSFRS) in multicenter clinical trials [J].
Cedarbaum, JM ;
Stambler, N .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1997, 152 :S1-S9
[4]   A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis [J].
Cudkowicz, ME ;
Shefner, JM ;
Schoenfeld, DA ;
Brown, RH ;
Johnson, H ;
Qureshi, M ;
Jacobs, M ;
Rothstein, JD ;
Appel, SH ;
Pascuzzi, RM ;
Heiman-Patterson, TD ;
Donofrio, PD ;
David, WS ;
Russell, JA ;
Tandan, R ;
Pioro, EP ;
Felice, KJ ;
Rosenfeld, J ;
Mandler, RN ;
Sachs, GM ;
Bradley, WG ;
Raynor, EM ;
Baquis, GD ;
Belsh, JM ;
Novella, S ;
Goldstein, J ;
Hulihan, J .
NEUROLOGY, 2003, 61 (04) :456-464
[5]  
Cudkowicz Merit, 2004, NeuroRx, V1, P273, DOI 10.1007/BF03206611
[6]   Trial of celecoxib in amyotrophic lateral sclerosis [J].
Cudkowicz, Merit E. ;
Shefner, Jeremy M. ;
Schoenfeld, David A. ;
Zhang, Hui ;
Andreasson, Katrin I. ;
Rothstein, Jeffrey D. ;
Drachman, Daniel B. .
ANNALS OF NEUROLOGY, 2006, 60 (01) :22-31
[7]  
Finkelstein DM, 1999, STAT MED, V18, P1341, DOI 10.1002/(SICI)1097-0258(19990615)18:11<1341::AID-SIM129>3.0.CO
[8]  
2-7
[9]  
Jacqmin-Gadda H, 2000, Biostatistics, V1, P355, DOI 10.1093/biostatistics/1.4.355
[10]   RANDOM-EFFECTS MODELS FOR LONGITUDINAL DATA [J].
LAIRD, NM ;
WARE, JH .
BIOMETRICS, 1982, 38 (04) :963-974